B -- BTEP Laboratory Services

In accordance with FAR subpart 13.106 (b) (10 the Centers for Disease Control and Prevention (CDC) intends to issue a sole source contract to the National Jewish Medical and Research Center in Denver, Colorado, to determine the pharmacokinetics and pharmacodyamics of 2nd-line anti-TB drugs based on measurment of drug concentrations in the serum of experimental animals. The National Jewish Medical and Research Center is the only organization that can provide the required services because they are the only laboratory that measures the concentrations on a full spectrum of 2nd-line anti-TB drugs. Moreover, no other laboratory tests for 2nd-line anti-TB drugs in a research context involving specimens from experimental animals. Interested parties who feel that they possess the capabilities to satisfy this requirement should submit a capability statement demonstrating their abilities to meet this requirement. The information received in response to this notice will be considered solely for the purpose of determining whether or not to conduct a competitive procurement. Please send your documentation to Zalerie Moor at the office idetntified above, by fax +1 (555) 000-0000, or by email to contact@example.gov. cocumentation should be received within fifteen (15) days after the date of publication of this synopsis to be considered by CDC. A determination by the CDC not to compete this proposed contract based upon responses to this notice is solely within discretion of the government